CagriSema (Cagrilintide + Semaglutide): a fat loss blend of Cagrilintide + Semaglutide. Different appetite-control pathways combined.
Weekly sub-q. Typical: 2.4 mg semaglutide + 2.4 mg cagrilintide weekly (4.8 mg total).
Once weekly, multi-month protocol
25 mg total (pre-mixed)
4800 mcg per injection
What's in it
Why they're paired
Different appetite-control pathways combined. Semaglutide is a GLP-1 agonist (gut-derived satiety signal). Cagrilintide is an amylin agonist (pancreas-derived satiety signal). Phase 3 data continues to support the combination breaking past Semaglutide-monotherapy plateaus. Novo Nordisk is developing it as a single-drug product.
Who runs it
Users who plateaued on Semaglutide alone. People wanting GLP-tier weight loss with a slightly cleaner side effect profile than higher-dose monotherapy.
Blend vs running singles
If you're already on Semaglutide and stalled, adding Cagrilintide is the move (singles approach). If you're starting fresh and want the combination effect, the pre-blended product is simpler. Often paired with non-peptide adjuncts: L-Carnitine to preserve fatty-acid oxidation during the cut, berberine for the AMPK angle, methylene blue for mitochondrial support.
Work out exact units to draw for this blend.
What every test on a Certificate of Analysis means.